Comparing SG&A Expenses: Zoetis Inc. vs Catalent, Inc. Trends and Insights

SG&A Expenses: A Tale of Two Companies

Zoetis Inc. vs Catalent, Inc.

In the ever-evolving landscape of the pharmaceutical industry, understanding the financial health of companies is crucial. This analysis focuses on the Selling, General, and Administrative (SG&A) expenses of Zoetis Inc. and Catalent, Inc. from 2014 to 2023.

Zoetis Inc., a leader in animal health, consistently outpaces Catalent, Inc. in SG&A expenses, reflecting its expansive operations. In 2023, Zoetis reported SG&A expenses over 2.1 billion, marking a 31% increase from 2014. Meanwhile, Catalent, a key player in drug development, saw its SG&A expenses grow by 179% over the same period, reaching approximately 935 million in 2024.

This trend highlights Zoetis's steady growth and Catalent's rapid expansion. However, the absence of 2024 data for Zoetis suggests a need for cautious interpretation. Investors and analysts should consider these insights when evaluating the strategic directions of these companies.